This strategic transaction will expand Sanofi’s healthcare portfolio in the United States. The integration of Qunol also strengthens Sanofi’s position in the vitamins, minerals and supplements (VMS) category of consumer healthcare, one of the fastest growing segments of the consumer healthcare market in the United States. Qunol is an established and profitable brand with double-digit growth and a leading position in the health and wellness market.

Sanofi’s acquisition of Qunol is subject to customary regulatory approvals and is expected to close in the Autumn. This transaction underscores Sanofi’s ongoing commitment to explore strategic development opportunities and provide innovative healthcare solutions to improve the quality of life for consumers.

Katia Wagner, Transaction Services Partner at Eight Advisory, said, “We are pleased to have supported Sanofi in this acquisition. It is in line with Sanofi’s commitment to capitalise on growth opportunities and create value for its Consumer Healthcare business. Qunol is a strong and growing brand that aligns with Sanofi’s vision to promote consumer health and wellness. We believe this transaction will strengthen Sanofi’s position in the U.S. VMS market and help meet the growing health needs of the population.

Eight Advisory’s team supporting this transaction: